StreetInsider.com News Articles

JPMorgan says large-cap biotech is back as profits and pipelines fuel upside

Thu, 28 May 2026 16:07:08 -0400

Investing.com -- J.P. Morgan has reinstated coverage on 14 large-cap biotechnology companies, arguing the sector is entering a major inflection point as pipeline successes increasingly translate into profitable and diversified commercial businesses.

The bank said several biotech firms are now achieving or nearing sustained profitability, supported by expanding product portfolios, strong clinical pipelines, and potential business development activity.

The firm assigned Overweight ratings to companies including Vertex Pharmaceuticals Inc (NASDAQ:VRTX), Alnylam Pharmaceuticals Inc (NASDAQ:ALNY), BeOne Medicines AG DRC (NASDAQ:ONC), United Therapeutics Corporation (NASDAQ:UTHR), Insmed Inc (NASDAQ:INSM), Ascendis Pharma AS (NASDAQ:ASND), Jazz Pharmaceuticals PLC (NASDAQ:JAZZ), Ionis Pharmaceuticals Inc (NASDAQ:IONS), Biomarin Pharmaceutical Inc

JPMorgan says large-cap biotech is back as profits and pipelines fuel upside

Thu, 28 May 2026 16:07:08 -0400

JPMorgan says large-cap biotech is back as profits and pipelines fuel upside

Thu, 28 May 2026 16:07:08 -0400

JPMorgan says large-cap biotech is back as profits and pipelines fuel upside

Thu, 28 May 2026 16:07:08 -0400

JPMorgan says large-cap biotech is back as profits and pipelines fuel upside

Thu, 28 May 2026 16:07:08 -0400

JPMorgan says large-cap biotech is back as profits and pipelines fuel upside

Thu, 28 May 2026 16:07:08 -0400

JPMorgan says large-cap biotech is back as profits and pipelines fuel upside

Thu, 28 May 2026 16:07:08 -0400

JPMorgan says large-cap biotech is back as profits and pipelines fuel upside

Thu, 28 May 2026 16:07:08 -0400

JPMorgan says large-cap biotech is back as profits and pipelines fuel upside

Thu, 28 May 2026 16:07:08 -0400

JPMorgan says large-cap biotech is back as profits and pipelines fuel upside

Thu, 28 May 2026 16:07:08 -0400

JPMorgan says large-cap biotech is back as profits and pipelines fuel upside

Thu, 28 May 2026 16:07:08 -0400

JPMorgan says large-cap biotech is back as profits and pipelines fuel upside

Thu, 28 May 2026 16:07:08 -0400

JPMorgan says large-cap biotech is back as profits and pipelines fuel upside

Thu, 28 May 2026 16:07:08 -0400

Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference

Wed, 27 May 2026 07:00:00 -0400

BRIDGEWATER, N.J., May 27, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the 2026 Goldman Sachs Annual Global Healthcare Conference in Miami on Tuesday, June 9, 2026, at 10:00 a.m. ET.

This event will be webcast live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com. This webcast will be archived for a period of 30

Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference

Wed, 27 May 2026 07:00:00 -0400

This event will be webcast live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com. This webcast will be archived for a period of 30

Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference

Wed, 27 May 2026 07:00:00 -0400

This event will be webcast live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com. This webcast will be archived for a period of 30

Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference

Wed, 27 May 2026 07:00:00 -0400

This event will be webcast live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com. This webcast will be archived for a period of 30

Form 144 INSMED Inc Filed by: Smith Michael Alexander

Fri, 22 May 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260522/26542631.html

Form 144 INSMED Inc Filed by: Smith Michael Alexander

Fri, 22 May 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260522/26542631.html

Form 4 INSMED Inc For: May 22 Filed by: Smith Michael Alexander

Fri, 22 May 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260522/26542102.html

Form 4 INSMED Inc For: May 22 Filed by: Smith Michael Alexander

Fri, 22 May 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260522/26542102.html

Form 4 INSMED Inc For: May 18 Filed by: Lewis William

Wed, 20 May 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260520/26528307.html

Form 4 INSMED Inc For: May 18 Filed by: Lewis William

Wed, 20 May 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260520/26528307.html

JPMorgan sees biotech sector at inflection point, resumes coverage on 14 Firms

Wed, 20 May 2026 15:10:43 -0400

Investing.com -- JPMorgan has reinstated ratings and price targets on 14 large-cap biotechnology companies, describing the sector as being at a critical “inflection point” as pipeline successes increasingly translate into profitable commercial franchises.

The bank’s analysts, led by Jessica Fye, noted that several firms have already achieved sustained profitability, while others are on the verge, setting the stage for margin expansion and long-term growth.

The report highlighted that companies such as Alnylam Pharmaceuticals Inc (NASDAQ:ALNY), BeOne Medicines AG DRC (NASDAQ:ONC), and Ascendis Pharma AS (NASDAQ:ASND) have transitioned into profitability, while Insmed and Ionis are close to doing so. JPMorgan sees diversification as another

JPMorgan sees biotech sector at inflection point, resumes coverage on 14 Firms

Wed, 20 May 2026 15:10:43 -0400